# ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis

> **NCT00063414** · PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.**

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Alicaforsen

## Key facts

- **NCT ID:** NCT00063414
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11-20
- **Primary completion:** 2005-03-24
- **Final completion:** 2005-03-24
- **Target enrollment:** — (—)
- **Last updated:** 2022-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00063414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00063414, "ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00063414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*